Healthcare Industry News: HSMN NewsFeed
News Release - October 25, 2010
BSD Medical Announces Purchase of BSD-500 Hyperthermia System by University Medical Center of Göttingen, GermanySALT LAKE CITY--(Healthcare Sales & Marketing Network)-- BSD Medical Corporation (NASDAQ:BSDM ) (the “Company” or “BSD”) announced today that the University Medical Center (UMC) of Göttingen, Germany, has purchased a BSD-500 Hyperthermia System (BSD-500). UMC was established in 1732 and is a center of scientific excellence in Europe and the most prominent medical center in Lower Saxony, Germany. The UMC is a premier research oriented facility whose mission is to care for both the health and the quality of life of its patients. UMC has 1,470 beds and 11,000 employees.
The Department of Radiation Oncology of UMC is chaired by Professor Clemens Hess, M.D. Ph.D. UMC plans to use the BSD-500 to deliver hyperthermia in combination with radiation therapy for the treatment of head and neck cancer and chest wall recurrences of breast cancer. The institution also plans to utilize hyperthermia combined with high and low dose rate brachytherapy to treat various tumors, including prostate cancer and breast cancer. The BSD-500 will start clinical operation in the second part of October 2010.
UMC Göttingen joins the growing family of hyperthermia facilities located in prestigious German University Medical Centers, including UMC Charité Berlin, UMC Grosshadern of the Ludwigs Maximilians University Munich, UMC Erlangen, UMC Düsseldorf, UMC Tübingen as well as Schlossbergklinik Oberstaufen and Klinik Bad Trissl of the Comprehensive Cancer Center of UMC Munich. The University Medical Centers in Munich, Düsseldorf and Erlangen all operate multiple BSD hyperthermia systems for treatment of various cancers using hyperthermia in combination with radiation therapy and/or chemotherapy.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.
Source: BSD Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.